[Alpha Tau in Yahoo Finance] Alpha Tau Receives FDA’s Breakthrough Device Designation for the Treatment of Recurrent GBM

Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is pleased to announce that it has received Breakthrough Device Designation for Alpha DaRT from the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent glioblastoma multiforme (GBM).

Read more here.